Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 26, 2021	Mar. 27, 2020
Net sales		$ 558.0	$ 665.8
Operating Income (Loss)		(17.5)	(6.3)
Depreciation and amortization		(145.3)	(197.6)
Employee Benefits and Share-based Compensation		(3.6)	(6.7)
Opioid-related litigation settlement gain (Note 11)		0.0	(16.8)
Non-restructuring impairment charges		(64.5)	0.0
Specialty Brands
Net sales		408.4	490.6
Operating Income (Loss)		212.1	220.5
Specialty Generics
Net sales		149.6	175.2
Operating Income (Loss)		31.7	63.2
Corporate, Non-Segment
Corporate and unallocated expenses	[1]	(22.6)	(57.5)
Depreciation and amortization		(169.6)	(223.1)
Restructuring and related charges, net		(0.4)	1.8
Separation Costs	[2]	(0.6)	(21.3)
Opioid-related litigation settlement gain (Note 11)	[3]	0.0	16.8
Operating Segments
Operating Income (Loss)		$ 243.8	$ 283.7

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

[2] Represents costs included in SG&A expenses, primarily related to professional fees and costs incurred in preparation for the Chapter 11 proceedings. As of the Petition Date, professional fees directly related to the Chapter 11 proceedings that were previously reflected as separation costs are being classified on a go-forward basis as reorganization items, net.

[3] Represents the change in the Settlement Warrants' fair value. Refer to Note 11 for further information.